209 related articles for article (PubMed ID: 26458935)
1. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis.
Lan Z; Fu D; Yu X; Xi M
Fam Cancer; 2016 Apr; 15(2):221-30. PubMed ID: 26458935
[TBL] [Abstract][Full Text] [Related]
2. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
3. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.
Schorge JO; Drake RD; Lee H; Skates SJ; Rajanbabu R; Miller DS; Kim JH; Cramer DW; Berkowitz RS; Mok SC
Clin Cancer Res; 2004 May; 10(10):3474-8. PubMed ID: 15161704
[TBL] [Abstract][Full Text] [Related]
5. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma.
Milivojevic M; Boskovic V; Atanackovic J; Milicevic S; Razic S; Kotlica BK
Eur J Gynaecol Oncol; 2013; 34(1):83-5. PubMed ID: 23590008
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
[TBL] [Abstract][Full Text] [Related]
8. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
[TBL] [Abstract][Full Text] [Related]
9. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
10. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
Mansha M; Gill A; Thomson PC
Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
[TBL] [Abstract][Full Text] [Related]
11. [Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy].
Mrochem-Kwarciak J; Mrochen-Domin I; Wojcieszek A; Deja R; Chmura A; Masłyk B; Nowara E; Kaleta B; Kołosza Z; Bartnik W
Ginekol Pol; 2011 Dec; 82(12):911-7. PubMed ID: 22384627
[TBL] [Abstract][Full Text] [Related]
12. Role of osteopontin in differential diagnosis of ovarian tumors.
Moszynski R; Szubert S; Szpurek D; Michalak S; Sajdak S
J Obstet Gynaecol Res; 2013 Nov; 39(11):1518-25. PubMed ID: 23875677
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma.
Živný JH; Leahomschi S; Klener P; Živný J; Haluzík M; Cibula D
Folia Biol (Praha); 2016; 62(6):258-262. PubMed ID: 28189149
[TBL] [Abstract][Full Text] [Related]
14. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic test for ovarian cancer composed of ovarian cancer symptom index, menopausal status and ovarian cancer antigen CA125.
Macuks R; Baidekalna I; Donina S
Eur J Gynaecol Oncol; 2011; 32(3):286-8. PubMed ID: 21797118
[TBL] [Abstract][Full Text] [Related]
17. Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis.
Wang YD; Chen H; Liu HQ; Hao M
Tumour Biol; 2014 Dec; 35(12):11799-808. PubMed ID: 25192720
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of serum human epididymis protein 4 and cancer antigen 125 in the patients with ovarian carcinoma: A protocol for systematic review and meta-analysis.
Dai HY; Hu F; Ding Y
Medicine (Baltimore); 2021 May; 100(21):e25981. PubMed ID: 34032711
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review.
Hu ZD; Wei TT; Yang M; Ma N; Tang QQ; Qin BD; Fu HT; Zhong RQ
PLoS One; 2015; 10(5):e0126444. PubMed ID: 25951060
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.
Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]